UCB company profile
Company profile
UCB has 9,000 employees and is headquartered in Brussels, Belgium.
Employing 9,000 people, UCB SA develops medicines for people with neurology and immunology conditions, serving patients worldwide. Epilepsy treatments such as Keppra and Vimpat sit alongside Neupro for Parkinson's disease, while Cimzia and Bimzelx address several inflammatory conditions, including plaque psoriasis and psoriatic arthritis. Evenity, for osteoporosis in postmenopausal women, and Fintepla, for Dravet and Lennox-Gastaut syndromes, add to the range, and the pipeline includes bepranemab for Alzheimer's disease and dapirolizumab pegol for systemic lupus erythematosus. The company also engages in contract manufacturing.
In the fiscal year ended December 2025, revenue reached 7.7 billion euros, up 25.8% from the previous year, and net profit came to 1.6 billion euros. The company was founded in 1925 and its headquarters are in Brussels, Belgium.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Belgium
- Headquarters
- Allée de la Recherche, 60, 1070, Brussels
- Employees
- 9,000
- Chief executive
- Jean-Christophe Tellier
- Founded
- 1925
- Fiscal year
- January - December
- Listing
- UCB · Euronext Brussels
- Currency
- EUR
- ISIN
- BE0003739530
- Website
- ucb.com
UCB and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| UCBUCB | Belgium | $62.48B | 9,000 | 29.5% | 26.2 |
| GenmabGMAB | Denmark | $32.21B | 3,244 | 30.6% | 47.0 |
| Financière de TubizeTUB | Belgium | $11.2B | 3 | -42,153.6% | 102.5 |
| ALK-AbellóALK.B | Denmark | $8.14B | 2,773 | 26.9% | 40.7 |
| ABIVAXABVX | France | $7.65B | 98 | -6,270.4% | — |
| Bachem HoldingBANB | Switzerland | $7.43B | 2,725 | 21.8% | 41.9 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
